Niranjan Kanesa-thasan - Jan 4, 2023 Form 4 Insider Report for Icosavax, Inc. (ICVX)

Role
Chief Medical Officer
Signature
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
Stock symbol
ICVX
Transactions as of
Jan 4, 2023
Transactions value $
-$1,421,162
Form type
4
Date filed
1/5/2024, 07:18 PM
Previous filing
Nov 14, 2022
Next filing
Feb 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Options Exercise $11.6K +13.8K +6.16% $0.84* 238K Jan 4, 2023 Direct
transaction ICVX Common Stock Options Exercise $77.6K +74.6K +31.39% $1.04* 312K Jan 4, 2023 Direct
transaction ICVX Common Stock Options Exercise $70.5K +11.9K +3.82% $5.90 324K Jan 4, 2023 Direct
transaction ICVX Common Stock Options Exercise $89.6K +5.97K +1.84% $15.00 330K Jan 4, 2023 Direct
transaction ICVX Common Stock Sale -$1.67M -106K -32.2% $15.70 224K Jan 4, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -13.8K -84.61% $0.00 2.51K Jan 4, 2023 Common Stock 13.8K $0.84 Direct F2
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -74.6K -63.89% $0.00 42.2K Jan 4, 2023 Common Stock 74.6K $1.04 Direct F3
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -11.9K -9.93% $0.00 108K Jan 4, 2023 Common Stock 11.9K $5.90 Direct F4
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -5.97K -4.8% $0.00 119K Jan 4, 2023 Common Stock 5.97K $15.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.70 to $15.78. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 25% of the shares subject to the option vested on April 1, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.
F3 25% of the shares subject to the option vested on January 14, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.
F4 25% of the shares subject to the option vested on March 19, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.
F5 1/48th of the shares subject to the option vest monthly following July 28, 2021, the vesting commencement date.